Through the direct activation of immune cells and the contribution to airway remodeling in asthma experimental studies (Lan et al., 2018; Hoi, Iskander & Morand, 2007), inhibitors of MIF prove to be a strategic therapeutic target for asthma; thus indicating the potential favorable benefits of the docked DCT-compounds. This evidence concerns the gene MIF and asthma.